| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Jagsonpal Pharmaceuticals Limited (NSE: JAGSNPHARM)
JAGSNPHARM Technical Analysis
1.5
| As on 24th Apr 2024 JAGSNPHARM SHARE Price closed @ 320.65 and we RECOMMEND Sell for LONG-TERM with Stoploss of 376.80 & Buy for SHORT-TERM with Stoploss of 304.18 we also expect STOCK to react on Following IMPORTANT LEVELS. |
JAGSNPHARMSHARE Price
| Open | 328.85 | Change | Price | % |
| High | 333.00 | 1 Day | -4.95 | -1.52 |
| Low | 316.30 | 1 Week | -0.80 | -0.25 |
| Close | 320.65 | 1 Month | 33.70 | 11.74 |
| Volume | 42977 | 1 Year | -35.90 | -10.07 |
| 52 Week High 478.55 | 52 Week Low 245.35 | ||||
NSE INDIA Most Active Stocks
| IDEA | 13.10 | -9.03% |
| SAIL | 164.65 | 8.14% |
| YESBANK | 25.45 | -0.78% |
| TATASTEEL | 165.55 | 2.73% |
| IRFC | 149.00 | 0.85% |
| SOUTHBANK | 29.10 | 1.04% |
| MRPL | 248.70 | 10.75% |
| SUZLON | 41.80 | -0.12% |
| BEL | 236.50 | 0.92% |
| RAMASTEEL | 14.00 | 2.56% |
NSE INDIA Top Gainers Stocks
| ROML | 63.05 | 19.98% |
| COMPUSOFT | 35.20 | 19.93% |
| SHRADHA | 78.55 | 19.83% |
| STEELCITY | 102.95 | 19.78% |
| WEIZMANIND | 142.25 | 19.59% |
| TEMBO | 240.90 | 18.61% |
| CHENNPETRO | 1075.00 | 15.82% |
| YUKEN | 1180.65 | 13.81% |
| ORIENTCEM | 230.50 | 12.85% |
| AEGISCHEM | 604.50 | 12.41% |
NSE INDIA Top Losers Stocks
| JAGSNPHARM Daily Charts |
JAGSNPHARM Intraday Charts |
Whats New @ Bazaartrend |
JAGSNPHARM Free Analysis |
|
|
JAGSNPHARM Important Levels Intraday
| RESISTANCE | 352.83 |
| RESISTANCE | 342.51 |
| RESISTANCE | 336.13 |
| RESISTANCE | 329.75 |
| SUPPORT | 311.55 |
| SUPPORT | 305.17 |
| SUPPORT | 298.79 |
| SUPPORT | 288.47 |
JAGSNPHARM Target April 2024
| 4th UP Target | 519.75 |
| 3rd UP Target | 451.22 |
| 2nd UP Target | 408.85 |
| 1st UP Target | 366.49 |
| 1st DOWN Target | 245.61 |
| 2nd DOWN Target | 203.25 |
| 3rd DOWN Target | 160.88 |
| 4th DOWN Target | 92.35 |
JAGSNPHARM Weekly Target
| 4th UP Target | 422.16 |
| 3rd UP Target | 388.82 |
| 2nd UP Target | 368.21 |
| 1st UP Target | 347.60 |
| 1st DOWN Target | 288.80 |
| 2nd DOWN Target | 268.19 |
| 3rd DOWN Target | 247.58 |
| 4th DOWN Target | 214.24 |
JAGSNPHARM Target2024
| 4th UP Target | 831.82 |
| 3rd UP Target | 689.77 |
| 2nd UP Target | 601.97 |
| 1st UP Target | 514.17 |
| 1st DOWN Target | 263.63 |
| 2nd DOWN Target | 175.83 |
| 3rd DOWN Target | 88.03 |
| 4th DOWN Target | -54.02 |
Jagsonpal Pharmaceuticals Limited ( NSE INDIA Symbol : JAGSNPHARM )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
JAGSNPHARM Synopsis Technicals View
| 50 Day EMA |
Close is Above EMA 50 (Short Term) |
Bullish | |
| 100 Day EMA | Close is Above EMA 100 (Mid Term) | Bullish | |
| 200 Day EMA | Close is Above EMA 200 (Long Term) | Bullish | |
| MACD (12 26 9) | MACD Line is Less Then SIGNAL Line | Bearish | |
| RSI (14) | RSI is Below 30 | Over Sold | |
| MFI (14) | MFI is Below 20 | Over Sold | |
| CCI (20) | CCI is Below -100 | Over Sold | |
| WILLIAM %R (14) | William %R is Below -80 | Over Sold | |
| ADX (14) | ADX is Above 20 & +DI is Below -DI | Down Trend | |
| PSAR | Stoploss For Long Buy | 24.39 | |
| 10 Day Avg Volume | Traded 89.98 % More then 10 Day Average Volume | ||
JAGSNPHARM Other Details
| Segment | EQ | |
| Market Capital | 4741837824.00 | |
| Sector | Healthcare | |
| Industry | Drug Manufacturers-Specialty & Generic | |
| Offical website | > | |
JAGSNPHARM Address
 |
||
JAGSNPHARM Latest News
JAGSNPHARM Business Profile
Jagsonpal Pharmaceuticals Limited develops and manufactures bulk drugs and pharmaceutical formulations in the areas of women health, pain and analgesics, and general medicine. It offers general medicines, such as allergy management, immunity and cell protection, gut and mind management, anti-infectives, and dentist and ENT range products; and women's healthcare products, including pregnancy care, and dysfunctional uterine bleeding complications and management products. The company also provides pain and analgesics products in the areas of pain management, and bone and joint care. It offers drugs in the form of tablets, capsules, and syrups. The company was founded in 1964 and is based in New Delhi, India. Jagsonpal Pharmaceuticals Limited is a subsidiary of Aresko Progressive Private Limited. Address: T-210 J, Shahpur Jat, New Delhi, India, 110049
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service